| Summary: | The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall survival in CLL patients in both first line and relapsed disease settings. Targeted drugs lack typical complications of chemotherapy, such as myelosupression. However, they have their specific side effects that require particular attention to avoid unjustified dose reduction and treatment cessation. The present review focuses on practical use of ibrutinib, the first inhibitor of Bruton’s tyrosinkinase.
|
|---|
